Clinical Trials Browser

Waldenstrom Macroglobulinemia × Rituximab × 1 year × Clear all

NCT04840602 2026-06-03

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07231952 2026-06-03

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05099471 2026-05-05

VIWA-1

Phase 2 Recruiting

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT01813227 2026-04-03

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

Phase 2 Completed

7 enrolled 10 charts

Waldenstrom Macroglobulinemia

NCT06561347 2026-03-31

ZEBRA

Phase 2 Recruiting

Waldenstrom Macroglobulinemia

NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Phase 1 Active not recruiting

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00492050 2026-03-11

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Phase 2 Active not recruiting

46 enrolled 10 charts

Waldenstrom Macroglobulinemia

NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1/2 Completed

55 enrolled 17 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Intraocular Lymphoma

NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Phase 2 Active not recruiting

33 enrolled 16 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02844322 2026-02-11

BDH-WM01

Phase 4 Completed

Waldenstrom Macroglobulinemia

NCT04624906 2026-02-04

BRAWM

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 2 FDA

LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT03620903 2025-12-05

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia

NCT05065554 2025-12-05

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia, Neuritis

NCT07259122 2025-12-02

ZBR in WM

Phase 2 Not yet recruiting

Waldenstrom Macroglobulinemia

NCT07169565 2025-09-11

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Phase 1 Not yet recruiting

Waldenstrom Macroglobulinemia